JANX — Janux Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1817713 ·
Last close
$10.71
Market Cap
$655.27M
52W High
$35.34
52W Low
$10.50
ADV30
995,683
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 9,289,000 — -31,258,000 -21,570,000 983,655,000 41,818,000 72,043,000
Jun 2026 10,267,000 — -31,690,000 -21,972,000 1,007,653,000 27,768,000 79,669,000
Mar 2026 3,733,000 — -34,213,000 -24,361,000 1,028,225,000 51,828,000 86,690,000
Dec 2025 0 — -42,401,000 -31,946,000 1,001,565,000 52,334,000 44,743,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-41,251,000
Investing CF
$7,351,000
Financing CF
$9,222,000
CapEx
$-674,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-1.64
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-397,715,000
Inventory
—
Receivables
$6,325,000
ST Investments
$943,145,000
EBIT TTM
$-143,555,000
Pretax Income TTM
$-102,592,000
Interest Exp TTM
—
Analysts
15

Yahoo Snapshot (yfinance, live)

Total Revenue
$23,289,000
EBITDA
$-137,704,000
Free Cash Flow
$-24,240,250
Enterprise Value
$153,326,640
Total Cash
$945,716,992
Total Debt
$20,380,000
Shares Out
61,183,417
Trailing EPS
$-1.59
Book Value
$14.90
ROE
-10.6%
ROA
-8.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 10,000,000 -157,667,000 -113,625,000 1,001,565,000 44,743,000 956,822,000 -82,235,000
Dec 2024 10,588,000 -98,847,000 -68,994,000 1,061,516,000 38,735,000 1,022,781,000 -43,814,000
Dec 2023 8,083,000 -72,979,000 -58,293,000 380,407,000 36,058,000 344,349,000 -50,575,000
Dec 2022 8,612,000 -67,091,000 -63,059,000 364,010,000 43,270,000 320,740,000 -42,922,000

TTM Snapshot

Revenues TTM
$24,000,000
NetIncome TTM
$-102,592,000
OpCashFlow TTM
—
Assets (Latest)
$1,007,653,000
Forward EPS
$-2.56

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $15.00 · spot: $10.31 · call volume: 280 · put volume: 947
Expected Move to 2027-01-15: ±$8.90 (86.32%) — implied range $1.41 – $19.21 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NVCT Nuvectis Pharma, Inc. $660.27M $19.20 —
ANNX Annexon, Inc. $661.95M $3.47 —
GERN GERON CORP $644.24M $1.00 —
SVA SINOVAC BIOTECH LTD $642.44M $6.47 —
BCAX Bicara Therapeutics Inc. $637.32M $9.60 —

News headlines (Yahoo Finance, 1h cache)

Janux Therapeutics Stock In Focus As Loss Narrows And Phase 1 Data Nears
2026-11-10 01:16 · Yahoo
Janux Reports Deep B-Cell Depletion in Initial Phase 1 Trial of JANX011; Shares Fall
2026-11-09 15:52 · Yahoo
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
2026-11-09 13:30 · Yahoo
Janux Therapeutics (JANX) Earnings Beat Brings Its Pricey Valuation Back Into Focus
2026-11-07 14:09 · Yahoo
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates
2026-11-05 21:10 · Yahoo
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
2026-11-05 21:02 · Yahoo
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
2026-11-02 21:02 · Yahoo
Janux Therapeutics (JANX) Stock Looks Above Fair Value Based On Sales
2026-10-29 08:24 · Yahoo
Janux Therapeutics (JANX), What Is Drawing Fresh Attention Now?
2026-10-13 09:11 · Yahoo
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
2026-09-14 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.